The expression level of DR6 is generally increased in various tumor tissues, including prostate, colorectal, lung, melanoma, gliomas, breast and ovarian cancers (Kasof et al., 2001; McNeal et al., 2016; Stegmann et al., 2019), suggesting an important role of DR6 in tumor development and progression. Here, TNFRSF21 is linked to ovarian cancer.